These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 2323818)
41. Relationship between structure and biological and protective activities of pertussis toxin. Sato H; Sato Y Dev Biol Stand; 1991; 73():121-32. PubMed ID: 1723387 [TBL] [Abstract][Full Text] [Related]
42. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Salmaso S; Mastrantonio P; Tozzi AE; Stefanelli P; Anemona A; Ciofi degli Atti ML; Giammanco A; Pediatrics; 2001 Nov; 108(5):E81. PubMed ID: 11694665 [TBL] [Abstract][Full Text] [Related]
43. Protective antigens of Bordetella pertussis mouse-protection test against intracerebral and aerosol challenge of B. pertussis. Sato H; Sato Y Dev Biol Stand; 1985; 61():461-7. PubMed ID: 2872127 [TBL] [Abstract][Full Text] [Related]
44. Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis. Ausiello CM; Urbani F; La Sala A; Lande R; Piscitelli A; Cassone A Dev Biol Stand; 1997; 89():315-20. PubMed ID: 9272365 [TBL] [Abstract][Full Text] [Related]
45. Modulation of Bordetella pertussis infection with monoclonal antibodies to pertussis toxin. Halperin SA; Issekutz TB; Kasina A J Infect Dis; 1991 Feb; 163(2):355-61. PubMed ID: 1703192 [TBL] [Abstract][Full Text] [Related]
46. Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin. Ginnaga A; Morokuma K; Aihara K; Sakou M; Imaizumi A; Suzuki Y; Sato H; Sato Y; Ueda K; Kuno-Sakai H Tokai J Exp Clin Med; 1988; 13 Suppl():59-69. PubMed ID: 2908528 [TBL] [Abstract][Full Text] [Related]
47. Development and clinical testing of an acellular pertussis vaccine containing genetically detoxified pertussis toxin. Rappuoli R; Pizza M; De Magistris MT; Podda A; Bugnoli M; Manetti R; Nencioni L Immunobiology; 1992 Feb; 184(2-3):230-9. PubMed ID: 1587545 [TBL] [Abstract][Full Text] [Related]
48. Comparison of pertussis toxin (PT)-neutralizing activities and mouse-protective activities of anti-PT mouse monoclonal antibodies. Sato H; Sato Y; Ohishi I Infect Immun; 1991 Oct; 59(10):3832-5. PubMed ID: 1894382 [TBL] [Abstract][Full Text] [Related]
49. Suppression of serum antibody responses by pertussis toxin after respiratory tract colonization by Bordetella pertussis and identification of an immunodominant lipoprotein. Carbonetti NH; Artamonova GV; Andreasen C; Dudley E; Mays RM; Worthington ZE Infect Immun; 2004 Jun; 72(6):3350-8. PubMed ID: 15155640 [TBL] [Abstract][Full Text] [Related]
50. Expression of pertussis toxin correlates with pathogenesis in Bordetella species. Monack D; Munoz JJ; Peacock MG; Black WJ; Falkow S J Infect Dis; 1989 Feb; 159(2):205-10. PubMed ID: 2464653 [TBL] [Abstract][Full Text] [Related]
51. Towards third-generation whooping cough vaccines. Rappuoli R; Pizza M; Podda A; De Magistris MT; Nencioni L Trends Biotechnol; 1991 Jul; 9(7):232-8. PubMed ID: 1370047 [TBL] [Abstract][Full Text] [Related]
52. Investigating pertussis toxin and its impact on vaccination. Coutte L; Locht C Future Microbiol; 2015; 10(2):241-54. PubMed ID: 25689536 [TBL] [Abstract][Full Text] [Related]
53. Immunogenicity and protective efficacy of a recombinant filamentous haemagglutinin from Bordetella pertussis. Knight JB; Huang YY; Halperin SA; Anderson R; Morris A; Macmillan A; Jones T; Burt DS; Van Nest G; Lee SF Clin Exp Immunol; 2006 Jun; 144(3):543-51. PubMed ID: 16734625 [TBL] [Abstract][Full Text] [Related]
54. Development of safer pertussis DNA vaccine expressing non-toxic C180 polypeptide of pertussis toxin S1 subunit. Kamachi K; Arakawa Y Vaccine; 2007 Jan; 25(6):1000-6. PubMed ID: 17050047 [TBL] [Abstract][Full Text] [Related]
55. Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. Mastrantonio P; Spigaglia P; Oirschot HV; van der Heide HGJ; Heuvelman K; Stefanelli P; Mooi FR Microbiology (Reading); 1999 Aug; 145 ( Pt 8)():2069-2075. PubMed ID: 10463173 [TBL] [Abstract][Full Text] [Related]
56. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704 [TBL] [Abstract][Full Text] [Related]
60. Use of pertussis toxin encoded by ptx genes from Bordetella bronchiseptica to model the effects of antigenic drift of pertussis toxin on antibody neutralization. Hausman SZ; Burns DL Infect Immun; 2000 Jun; 68(6):3763-7. PubMed ID: 10816544 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]